Aurora Kinase A Regulates Trained Immunity via SAM Metabolism

Study Background and Research Question

Trained immunity describes the phenomenon whereby innate immune cells, such as monocytes and macrophages, develop a memory-like phenotype that enables them to respond more robustly to secondary challenges, independent of adaptive immunity. This process is characterized by metabolic reprogramming and sustained epigenetic modifications, including histone methylation, which together enhance the transcriptional response to subsequent stimuli. However, the regulatory mechanisms connecting cellular metabolism with the chromatin landscape during trained immunity remain incompletely understood (Li et al., 2025).

The reference study by Li et al. addresses a pivotal question: How does Aurora kinase A (AurA), a serine/threonine kinase well known for its role in mitosis and overexpressed in various tumors, regulate the metabolic and epigenetic machinery underlying trained immunity? Specifically, the authors investigate whether AurA influences the availability of S-adenosylmethionine (SAM), a critical methyl donor for histone modifications, during β-glucan-induced trained immunity in macrophages.

Key Innovation from the Reference Study

The central innovation of Li et al. is the identification of AurA as a key regulator of trained immunity through its control of endogenous SAM metabolism. The study demonstrates that pharmacological or genetic inhibition of AurA disrupts the induction of trained immunity by β-glucan, primarily by limiting intracellular SAM pools. This metabolic constraint reduces histone methylation marks (H3K4me3, H3K36me3) at promoters of inflammatory genes, thereby suppressing their expression upon secondary challenge (Li et al., 2025).

These results establish a mechanistic link between a canonical cell cycle kinase, metabolic flux through the methionine/SAM pathway, and epigenetic reprogramming of innate immune cells. The work highlights the mTOR–FOXO3–GNMT signaling axis as the conduit through which AurA modulates SAM homeostasis, glycine N-methyltransferase (GNMT) expression, and ultimately, the epigenetic state of trained macrophages.

Methods and Experimental Design Insights

Li et al. employed a rigorous and multifaceted experimental approach to dissect the role of AurA in trained immunity:

• Innate Immune Training Model: Mouse bone marrow-derived macrophages (BMDMs) were exposed to β-glucan to induce trained immunity, followed by a rest period and secondary stimulation.
• AurA Inhibition: Both pharmacological inhibitors and genetic knockdown strategies were used to suppress AurA activity during the training phase.
• Chromatin Accessibility and Transcriptomics: ATAC-seq and RNA-seq were utilized to assess changes in chromatin landscape and gene expression profiles under conditions of AurA inhibition.
• Metabolomics: Targeted metabolomic assays quantified intracellular SAM levels after AurA inhibition.
• Epigenetic Profiling: ChIP-qPCR and Western blotting measured H3K4me3 and H3K36me3 enrichment on promoters of key inflammatory genes (e.g., Il6, Tnf).
• In Vivo Tumor Models: The functional relevance of AurA in trained immunity was tested by evaluating the effect of β-glucan-induced training on tumor growth in mice, with and without AurA inhibition.

This comprehensive suite of assays enabled the authors to parse out direct effects on metabolic, epigenetic, and functional outputs in both in vitro and in vivo contexts.

Protocol Parameters

• assay: β-glucan training of BMDMs | value_with_unit: 5 μg/mL β-glucan for 24 h | applicability: mouse macrophage trained immunity models | rationale: Standard dose for robust induction of trained phenotype | source_type: paper
• assay: AurA inhibitor (pharmacological) | value_with_unit: workflow recommendation—use a highly selective Aurora A kinase inhibitor at 100 nM–1 μM | applicability: in vitro suppression of AurA activity | rationale: Range shown to induce apoptosis and block AurA in cell lines | source_type: workflow_recommendation
• assay: SAM quantification | value_with_unit: LC-MS/MS, normalized to protein content | applicability: metabolic profiling in immune cells | rationale: Direct measurement of methyl donor pools | source_type: paper
• assay: ChIP-qPCR for H3K4me3/H3K36me3 | value_with_unit: relative enrichment at Il6/Tnf promoters | applicability: assessment of chromatin state changes | rationale: Epigenetic readout of trained immunity | source_type: paper

Core Findings and Why They Matter

The major findings of the study can be summarized as follows:

• AurA is essential for trained immunity: Inhibition of AurA, either pharmacologically or genetically, abrogated the enhanced inflammatory response characteristic of β-glucan-trained macrophages (Li et al., 2025).
• Chromatin accessibility is restricted by AurA inhibition: ATAC-seq and RNA-seq revealed that AurA blockade reduced accessibility and transcription of genes in pro-inflammatory pathways, including JAK-STAT, TNF, and NF-κB.
• AurA regulates SAM metabolism via mTOR–FOXO3–GNMT: Inhibiting AurA led to nuclear translocation of FOXO3 and increased GNMT expression, which together caused a reduction in intracellular SAM levels. This effect translated to diminished histone methylation (H3K4me3 and H3K36me3) at inflammatory gene loci.
• Functional impact in tumor models: The protective, tumor-suppressive effects of β-glucan-induced trained immunity were lost when AurA activity was blocked, demonstrating the physiological relevance of this pathway in vivo.

Collectively, these results position AurA as a metabolic-epigenetic gatekeeper in innate immune memory, with implications for both cancer biology and immunometabolic research. They also highlight a mechanistic bridge between oncogenesis and immune training, as both processes involve AurA-mediated regulation of methyl donor metabolism and chromatin dynamics (Li et al., 2025).

Comparison with Existing Internal Articles

Recent internal resources have extensively discussed the role of Aurora A kinase in cancer biology, oncogenesis, and apoptosis:

• Translating Mechanistic Insights into Strategic Leverage provides a translational overview of MLN8237 (Alisertib), emphasizing its selectivity and practical advantages for dissecting Aurora A pathway roles in tumor progression.
• MLN8237: Precision Targeting of Aurora A Kinase explores mechanistic and systems-level insights into how selective Aurora A inhibition can dissect apoptotic and cell cycle mechanisms in cancer biology.
• MLN8237: Selective Aurora A Kinase Inhibitor offers protocol recommendations and experimental troubleshooting for using MLN8237 in tumor growth inhibition and apoptosis induction workflows.

While these articles focus on cancer and apoptosis, Li et al. extend the functional repertoire of Aurora A kinase inhibition to innate immune memory and metabolic-epigenetic crosstalk. This represents a novel intersection between established cancer biology workflows and emerging immunometabolic research, suggesting that tools such as MLN8237 (Alisertib) could be leveraged beyond traditional oncology studies.

Limitations and Transferability

Despite the comprehensive nature of this study, several limitations should be acknowledged:

• Species and context specificity: The findings were established in mouse macrophages and mouse tumor models. While the basic metabolic and epigenetic mechanisms are conserved, direct extrapolation to human immunology or clinical settings should be approached cautiously.
• Pharmacological vs. genetic inhibition: Off-target effects of kinase inhibitors, even those as selective as MLN8237, should be considered. Genetic models can provide complementary specificity.
• Model system constraints: The reliance on β-glucan as the trained immunity inducer may not capture the full spectrum of stimuli relevant in human disease or infection.
• Tumor model complexity: The interplay between trained immunity, tumor microenvironment, and systemic factors remains incompletely defined (Li et al., 2025).

Overall, these limitations suggest that while the mechanistic insights are robust, validation in additional models and systems will strengthen the translational potential.

Research Support Resources

For researchers seeking to investigate Aurora A kinase function in cancer biology or trained immunity, selective inhibitors such as MLN8237 (Alisertib) (SKU A4110) are valuable tools due to their high specificity and well-characterized pharmacological profile (internal article). MLN8237 has been shown to induce apoptosis in tumor cells and inhibit tumor growth in animal models, and can be incorporated into protocols exploring metabolic and epigenetic regulation in immune or cancer cell systems (workflow_recommendation).

For further guidance on experimental design, protocol optimization, and troubleshooting for Aurora A kinase inhibitor applications in cancer or immunometabolic research, refer to the internal resources linked above.